COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Fundamental Risk Analysis including financial ratios, debt levels, liquidity, and sustainability metrics. Compare against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Fundamental Risk Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.

Debt-to-Equity Ratio

0.52

Increased from previous period

D/E ratio exceeding 1.5x Medical - Pharmaceuticals median of 0.02. Howard Marks would check for debt covenant compliance and refinancing risks.

Net Debt-to-EBITDA

0.03

Increased from previous period

Exceptionally low net debt at less than half the Medical - Pharmaceuticals median of 2.12. Joel Greenblatt would praise this conservative approach, but verify Operating Margins versus peers.

Interest Coverage Ratio

36.47

Decreased from previous period

Coverage of 36.47 versus zero Medical - Pharmaceuticals median interest expense. Walter Schloss would verify if our leverage provides advantages.

Current Ratio

0.90

Increased from previous period

Current ratio 50-75% of Medical - Pharmaceuticals median of 1.49. Martin Whitman would look for hidden assets or working capital optimization.

Intangibles-to-Total-Assets Ratio

0.43%

Increased from previous period

Intangibles 1.25-1.5x Medical - Pharmaceuticals median of 0.29%. Martin Whitman would scrutinize acquisition strategy and impairment risks.

Select Chart Metric:

3349.T Fundamental Risk Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Debt-to-Equity Ratio

0.52

Increased from previous period

D/E ratio exceeding 1.5x Medical - Pharmaceuticals median of 0.02. Howard Marks would check for debt covenant compliance and refinancing risks.

Net Debt-to-EBITDA

0.03

Increased from previous period

Exceptionally low net debt at less than half the Medical - Pharmaceuticals median of 2.12. Joel Greenblatt would praise this conservative approach, but verify Operating Margins versus peers.

Interest Coverage Ratio

36.47

Decreased from previous period

Coverage of 36.47 versus zero Medical - Pharmaceuticals median interest expense. Walter Schloss would verify if our leverage provides advantages.

Current Ratio

0.90

Increased from previous period

Current ratio 50-75% of Medical - Pharmaceuticals median of 1.49. Martin Whitman would look for hidden assets or working capital optimization.

Intangibles-to-Total-Assets Ratio

0.43%

Increased from previous period

Intangibles 1.25-1.5x Medical - Pharmaceuticals median of 0.29%. Martin Whitman would scrutinize acquisition strategy and impairment risks.

Select Chart Metric: